Munger Mode rating: 2 out of 5 — Sell. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Price used: about $272 per share. This is the November 6 quote cited with RBC's raised price target. The stock set a 52-week high on November 5 after earnings. I could not find a verified closing print, so every valuation figure below carries roughly ±3% uncertainty on price. The conclusion would not change within that band. Figures from the 10-Q are exact. Anything from before fiscal 2027 or from competitors is from memory and marked "approximately." Cardinal Health moves a large share of America's prescription drugs from manufacturers to pharmacies and hospitals. It also makes and distributes hospital supplies. It is a good enough business and the quarter was excellent. Non-GAAP EPS rose 28% to $3.26, and management raised fiscal 2027 guidance to $12.80–$13.00. The stock has run to roughly 21 times the midpoint of that guidance. Our problem is not the quarter.
Recent filings analysed: 8-K (2026-11-05), 10-Q (2026-11-05), 8-K (2026-10-01), DEF 14A (2026-09-21).
Stock screener · Superinvestor 13F holdings · Analyst sentiment